Rome, 24-25 may 2019
- Welcome
Stefania Gori, AIOM National President
SESSION I
A CHANGING WORLD…
- Response Predictive factors to immunotherapeutic drugs from PDL-1 to Tumor Mutational Burden
- The pathologist
G. Troncone, E. Vigliar - The pharmacologist
R. Danesi
- The pathologist
- The tumor microenvironment and new drugs
F. Cognetti, V. Vaccaro
SESSION II
UNANSWERED QUERIES
- “Driver” mutation and “Passenger” mutation: what is the clinical meaning?
S. Tommasi - The new immune-related response criteria (iRECIST): are always adequate
G. Lo Russo - The design and conduct of clinical trials in the era of precision oncology: what is changing?
E. De Luca, M. Di Maio
SESSION III
BRCA MUTATED OVARIAN CARCINOMA
- AIOM-SIGU-SIBIOP-SIAPEC-IAP 2019 recommendations
L. Cortesi - The use of new genomic technologies in BRCA mutated ovarian cancer patients: what information?
E. Capoluongo - Germinal pharmacogenetics
G. Toffoli
SESSION IV
ONCOGENE-ADDICTED NSCLC
- The development of resistances: clinical impact and therapeutic strategies
M. Del Re - Liquid biopsy recommendations AIOM -SIAPEC-IAP-SIF-SIBioC
A. Russo - Criteria of response during therapies in TKI: clinical or molecular criteria?
E. Bria - The new targets: ROS1, MEK, NTRK
A. Delmonte
SESSION V
COLORECTAL CARCINOMA
- Definition, effect, clinical course, therapies
S. Lonardi - New therapies and scientific evidence
F. Morano - Position of regulatory bodies: FDA, EMA, AIFA
R. Bordonaro
SESSION VI
MALIGNANT MELANOMA, CEREBRAL AND UROLOGICAL NEOPLASMS
- 2019: adjuvant treatment of malignant melanoma
V.Chiarion Sileni - New targets in brain neoplasms
G. Lombardi - BRCA2 and prostate carcinoma
G. Procopio
SESSION VII
BREAST CANCER
- PI3KA mutations and ER mutations: what impact on the outcome of breast cancer patients?
- The pharmacologist
G. Minotti - The oncologist
A. Fabi
- The pharmacologist
- BRCA mutated metastatic breast cancer: What is the role of PARP-I?
V. Guarneri - Immunotherapy in breast cancer: what evidence?
V. Sini
SESSION VIII
NEW FRONTIERS
- Radio receptor therapy
S. Severi - Radiomics
E. Neri
SESSION IX
THE AGNOSTIC-TISSUE PRECISION MEDICINE: AN EMERGING APPROACH
- Rational and therapeutic bases
P. Marchetti - New targets: are they always clinically useful?
F. Montemurro - Ongoing clinical studies
M. Biffoni, P. Marchetti - Patients’ requests
F. Nicolis - Reading:
The importance of interdisciplinary working groups in the age of precision oncology. The Molecular Tumor Board (MTB): from clinical indications to regulatory contexts
P. Conte
